Skip to content

Adding Motion to Contact: A New Model for Low-cost Family Centered Very-early Onset Intervention in Very Preterm-born Infants

Adding Motion to Contact: A New Model for Low-cost Family Centered Very-early Onset Intervention in Very Preterm-born Infants

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05542108
Acronym
NTM
Enrollment
24
Registered
2022-09-15
Start date
2021-09-07
Completion date
2024-01-30
Last updated
2022-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Injuries, Premature Birth

Keywords

Early Intervention, Family-Centered Care, Neonatology, High-Risk Infant, Sensory Motor Stimulation, Maternal Voice, Tactile stimulation, Kinesthetic stimulation

Brief summary

This project is a Randomised Clinical Trial that includes a tactile-kinesthetic somatosensory stimulation or family centred education intervention with families of preterm infants at risk for sensori-motor disorders. This is a study will be based on the adaptation of the intervention previously described and published by Guzzetta and colleagues (2009), and will include an improved and increased kinesthetic component, to be performed in infants born very prematurely and preterm infants with a documented brain injury. The intervention will start in neonatology during the infant hospitalization and continue at the child's home until two months of correct age.

Detailed description

Preterm babies, specifically with gestational age \< 33+6 weeks, will be recruited and assigned (randomized) into an a Multisensory stimulation + Family Education Group (MSG) or a Family Education Only Group (FEG). When the clinical condition of the child is stable and after a short training, parents of the MSG will be asked to carry out up to two treatment sessions per day with their child, until they reach the 8th post-term week. Sessions will initially be carried out together with a therapist who will have the task of transmitting the necessary skills to parents/caregivers. The therapist will assist parents through practical demonstrations, theoretical explanations and by answering the parents' questions. The treatment will consist of sessions of approximately 25-30 minutes. The main purposes of the intervention will be clearly explained to the parents, and in particular the goal of maintaining a calm and natural interaction during the session. In addition, all families will receive the evidence-based program of Family Education which is based on the promotion of the parent-child relationship through the recognition of behavioral states, methods of interaction, facilitation strategies in the relationship. It takes its conceptual basis from the Mother Infant Transaction Program (MITP). It is a specific and re-adapted version for the preterm infant hospitalized in NICU The family education group sessions involve about 6 meetings (1-2 a week) of 30-45 minutes that are carried out during the hospitalization in the NIC directly at the child's bed between the operator and one or both parents. Each meeting involves the discussion of one of the following topics.

Interventions

BEHAVIORALMultisensory Stimulation and Family Education Group

Bedside intervention directly with infant with trained healthcare providers and parents. Includes two parts: twice daily multisensory stimulation sessions and separate family education meetings completed with individual infant parent/s and trained operator.

BEHAVIORALFamily Education Only Group (FEG)

Bedside intervention directly with infant with trained healthcare providers and parents. Includes family education meetings completed with individual infant parent/s and trained operator.

Sponsors

IRCCS Fondazione Stella Maris
CollaboratorOTHER
Azienda Ospedaliero, Universitaria Pisana
CollaboratorOTHER
Azienda Ospedaliero-Universitaria Careggi
CollaboratorOTHER
University of Pisa
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

Investigator and Outcomes assessors are blind to the group assignment of the infant. Care provider (Parents and Research staff supporting parents in intervention can not be masked to the group assignment).

Intervention model description

Two intervention groups, Randomised Controlled Trial

Eligibility

Sex/Gender
ALL
Age
1 Weeks to 10 Weeks
Healthy volunteers
No

Inclusion criteria

* premature infants born \<29 weeks of gestation age or premature infants (born \< 33+6 weeks gestation age) with a documented brain injury .

Exclusion criteria

* Clinical instability, based on standard medical evaluation of preterm infants (eg: children with mechanical ventilation or under sedation) * Genetic-malformative conditions

Design outcomes

Primary

MeasureTime frameDescription
General Movements (GM)10-16 weeks corrected ageThe quality of general movements (based on standard observation of infant movements) will be assessed
Electroencephalogram (EEG)3 months corrected ageThe EEG inter-burst interval, asymmetries and global and local spectral power will be analysed

Secondary

MeasureTime frameDescription
Developmental outcome assessment12 months corrected ageBayley Scales of Infant Development Third Edition will be conducted including the Cognitive, Language (Receptive & Expressive), Motor (Gross & Fine), Social-Emotional and Adaptive sub scales. Each sub scale score will be calculated based on the age (months of age) of the infant at the time assessment. Higher scores mean a better outcome.

Other

MeasureTime frameDescription
Family well-being questionnairesBefore discharge from the Neonatal Unit (on average at 5 weeks post term age), 3, 6, 12 months corrected ageThe Infant Toddler Quality of Life QuestionnaireTM (ITQOL)
Family well-being questionnaireBefore discharge from the Neonatal Unit (on average at 5 weeks post term age), 3, 6, 12 months corrected ageEdinburg Postnatal Depression Scale (EPDS)

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026